Arachidonic acid, the specific precursor of prostaglandin synthesis, increased PCE2 synthesis twofold, and significantly inhibited AVP-and DDAVP-stimulated water flow by 60 and 75%, respectively. Naproxen and acetaminophen inhibited prostaglandin synthesis and enhanced water flow in response to AVP and DDAVP (44-54%).
INTRODUCTION
Arginine vasopressin (AVP)1 increases the osmotic water flow across the mammalian collecting tubule and the toad urinary bladder (1) . There is strong evidence that this response can be influenced by prostaglandins. Specifically, administration of exogenous prostaglandin (PG)E, or E, can markedly inhibit the response of the toad bladder (2) (3) (4) and isolated collecting tubule (5) to AVP. Inhibition of endogenous prostaglandin synthesis by cyclo-oxygenase inhibitors, on the other hand, enhances the response to AVP, both in vitro in toad bladder (3) and in vivo in animals (6, 7) and man (6) .
Zusman et al. (8) have proposed that coincident with its effect on water permeability, vasopressin stimulates prostaglandin biosynthesis, completing a negative feedback system. This proposal is based on their findings of increased PGE synthesis in vasopressintreated toad bladders as measured by means of an indirect radioimmunoassay system. This concept is not easily reconciled with several other studies or with our present results, however. Earlier studies by Wong et al. (9) reported that AVP did not increase toad bladder PGE production as measured by bioassay. Several recent reports using a variety of in vitro systems have suggested that it is the pressor rather than the antidiuretic activity of vasopressin that affects prostaglandin synthesis in rat renomedullary interstitial cells (10) and isolated perfused rabbit kidney (I11). Deamino-8-D-arginine vasopressin (DDAVP), the nonpressor, highly antidiuretic analogue of AVP, did not stimulate prostaglandin synthesis in these systems, however (10, 11) . Studies on rats with congenital diabetes insipidus have shown increases in urinary prostaglandin excretion in response to DDAVP (12, 13) , whereas DDAVP does not increase urinarv PGE2 excretion in human central diabetes insipidus (14, 15) . The possibility remains that chronic administration of DDAVP may stimulate prostaglandin synthesis in the mammalian collecting tubule either directly or indirectly, through, for example, changes in medullary composition or blood flow. Although not entirely clear, these data thus raise the possibility that it is not the primary antidiuretic activity of vasopressin on the collecting tubule, but rather its pressor activity elsewhere in the kidney or secondary phenomena, that stimulate renal prostaglandin synthesis. This concept is in contrast to the one proposed by Zusman et al. (8) , which suggested that vasopressin stimulates prostaglandin synthesis as an integral part of its antidiuretic activity in the toad bladder, an analogue of the mammalian collecting tubule.
We have reexamined prostaglandin synthesis in both the whole toad bladder and isolated epithelial cells, the vasopressin target cells, using specific radioimmunoassays and thin-layer radiochromatography. Our results confirm that the toad bladder produces PGE2 and thromboxane (TX)A2. Neither AVP nor DDAVP produced any change in prostaglandin synthesis, however, whereas agents that caused inhibition and stimulation of endogenous prostaglandin synthesis caused marked alterations in the water permeability response. We therefore propose an alternate hypothesis to characterize the interrelations among vasopressin, water permeability, and prostaglandins in the toad bladder that is not dependent on hormonal stimulation of prostaglandin synthesis. Our results also support the concept that the in vivo increase in prostaglandin synthesis with AVP administration is the result of the hormone's pressor activity, probably on the renal interstitial cells. Finally, the possibility remains that vasopressin may indirectly influence prostaglandin synthesis and excretion through changes in medullary solute composition or blood flow.
METHODS
WVater flotw stuidies. Female Dominican toads (Btufo marinus, National Reagents, Bridgeport, Ct.) were doubly pithed, glass bungs were tied onto both hemibladders in situ, and the hemibladders were excised. Care was taken to assure that the paired hemibladders were of equal size. Paired hemibladders were then randomly assigned to control or experimental groups. Radioimmunoassay for prostaglandins and thromboxane.
iPGE2, iPGE,, and iPGF2a, content was measured by the radioimmunoassay method of Dray et al. (20) , using specific antisera supplied by Boehringer Mannheim Biochemicals, Indianapolis, Ind., or the Institut Pasteur, Paris, France. Antisera from these two sources had identical cross-reactivities and binding constants, and yielded comparable standard curves. Cross-reactivity (at B/Bo = 0.5) for the PGE2 antisera was 3.2% with PGEI, 0.02% with PGA2, 0.01% with PGF2,,, 0.15% with 13,14-dihydroPGE2, 0.11% with 13,14-dihydro-15-ketoPGE2, and 0.01% with PGB2. Cross-reactivity (at B/Bo = 0.5) for the PGE, antisera was 15% with PGE2, 0.03% with PGA2, 0.05% with PGF2,,, and <0.00001% PGB2.
Cross-reactivity (at B/Bo = 0.5) for the PGF2,, antisera was 0.25% with PGE1, 0.15% with PGE2, and <0.1% with PGA2 and PGB2-iTXB2, the stable metabolite ofTXA2, was determined by the same technique using a specific antiserum supplied by Seragen, Inc., Boston, Mass. Cross-reactivity for this antiserum (at B/Bo = 0.5) was 2.52% with PGD2, 0.26% with PGE2, 0.07% with PGF2G,f, 0.05% with 6-ketoPGFlG,,, and <0.05% with PGA2-Final antibody titer was 1/4,000 for anti-TXB2, 1/5,Q00 for anti-PGE2, 1/36,000 for anti-PGF2., and 1/54,000 for anti-PGE, (20 The minimal detectable amounts of the various prostaglandins in the radioimmunoassay were PGE, or PGE2, 1-2 pg; TXB2, 1 pg; and PGF2S, 5 pg/0.1-ml sample aliquot. England Nuclear, specific activity 36.5 mCi/mmol) in toluenemethanol (9:1) was dried under nitrogen and resuspended in Ringer's or Ringer's containing naproxen (100 ,uM). Aliquots of serosal media were then removed at 0 and 30 min. These samples were immediately acidified to pH 3.0-3.5 with 1 N HCI; crystalline NaCl was added and then extracted twice in an equal volume of ethyl acetate. The aqueous layer was discarded and the organic layer evaporated to dryness under a stream of nitrogen. The sides of the tubes were washed down with ethyl acetate and spotted along with authentic standard solutions ofarachidonic acid, PGE2, TXB2, and PGA2 on precoated, silica gel 60 thin-layer chromatography plates (E. Merck Reagents, Elmsford, N. Y.). The plates were developed in solvent system I (the organic phase of ethyl acetate:glacial acetic acid:iso-octane:H20 [11:1:5:10]) or solvent system II (chloroform:methanol:acetic acid:H20 [98:8: 1:0.8]). Standards were identified by iodine staining. Sample lanes were cut into 5-mm strips, immersed in liquid scintillation cocktail (National Diagnostics, Inc., Somerville, N. J.), and radioactivity determined by liquid scintillation counting.
Metabolism ofexogenous [3H]PGE2. Paired hemibladders were incubated for 30 min in a serosal bath containing 1 ,zCi [5,6,8,11,12,14,15- Ringer's were then acidified, extracted, and processed by thin-layer chromatography in solvent system I, as described above.
Determination of prostaglandin synthesis from exogfenous ["4C ] arachidonic acid in epithelial cell suspensions. Epithelial cell suspensions were prepared as above. Equal volumes of the resuspended cells were incubated for 30 min in either regular Ringer's or Ringer's containing naproxen (100 ,tM).
The suspensions were then centrifuged, the supernatant solutions discarded, and the pellets resuspended in Ringer's or Ringer's plus naproxen. The suspensions were then placed in test tubes containing 0.5 ,uCi [14C]arachidonic acid. The suspensions were incubated for 30 min at 20°C in a shaking bath (40 cycles/min), then cooled to 40C and centrifuged at 1,000 rpm for 2 min. The supernatant solution was immediately removed and acidified, and aliquots were processed for thin-layer chromatography in solvent system I, II, or III (diethyl ether:methanol:acetic acid [90:1:2]).
Determination ofAVP's effects oni a raichidonic acid release and prostaglandin synthesis in bladders pretreated wcith radiolabeled ar(achidonic acid. Paired hemibladders were incubated overnight (18 h) in Ringer's containing glucose (5 mM), penicillin (100 U/ml), streptomycin (100 U/ml), and [1-'4C]arachidonic acid (n = 4 pairs). A total of 1 dACi of ['4C]arachidonic acid was added to each serosal bath and 0.4 ,uCi to each mucosal bath. The bladders were then washed three times by replacing the serosal and mucosal baths every 30 min with Ringer's and Ringer's diluted 1:10 with distilled H20, respectively. Nonincorporated '4C-labeled products were removed with the initial bath and first wash (98% of the total nonincorporated counts removed). Counts appearing in the second and third wash reached a plateau. After a third washing, the baths were changed again, and AVP (13 nM) was added to the serosal bath of the experimental hemibladder. Total radioactivity of the serosal and mucosal solutions was determined before and after the 18-h incubation, at the end of each wash, and at the end of the experimental period. Water flow was measured over 30 min. At the end of the experimental period, the serosal solutions were removed, 10 ml extracted, and thin-layer radiochromatography performed in solvent system II. Recovery of 14C label was 70-80% for both control and experimental solutions during the extraction process. At the end of the experiment the bladders were emptied, blotted dry inside and out, and dissolved in 5 ml of IN NaOH; radioactivity was then counted.
An identical series of experiments (n = 4 pairs) was performed using [5,6,8,9,11,12,14,15-3H(N) ]arachidonic acid with 4 ,uCi added to the serosal bath and 1 ,uCi added to the mucosal bath of each hemibladder (specific activity 62 Ci/mmol, New England Nuclear).
All values are expressed as the means±the standard error of the mean. In intact bladder sttudies, the results in one hemibladder are compared with those in the paired hemibladder by the method of paired analysis (22 (Table I) .
We next investigated the effects of acetaminophen on basal and DDAVP-stimulated water flow. Acetaminophen has been reported to enhance the response to AVP in toad bladder (23, 24) and have antidiuretic activity in human central diabetes insipidus (25) . Recently this compound has been found to inhibit prostaglandin synthesis in rat renal medullary slices (26) .
In our studies, treatment of bladders with acetaminophen (300 ,uM) led to a response similar to that seen with naproxen. Basal water flow was not affected. The water flow in response to 130 nM DDAVP was 25.9±3.1 ,ul/min in control hemibladders and 37.2 ±+3.5 ,ul/min in acetaminophen-treated bladders, a 44% enhancement (Table I) .
To determine whether the effects of naproxen and acetaminophen were additive, paired hemibladders were incubated in naproxen (100 ,uM) and the experi- Naproxen and acetaminophen were added to the serosal baths 15 min before the basal period. Basal water flow was measured over 30 (Table I) . Thus, acetaminophen would appear to share a common mechanism ofaction with naproxen in the toad bladder. Arachidonic acid (10 ,uM), the specific precursor of prostaglandins, was administered to experimental hemibladders to stimulate endogenous prostaglandin production. Basal water flow was not affected. However, the response to DDAVP (130 nM) and AVP (13 nM) was markedly inhibited by administration of arachidonic acid (10 ,M) (Table II) .
Prostaglandin synthesis in intact bladders. Using specific radioimmunoassay for iPGE2, iPGE,, and iPGF2a,,, we determined the rates of synthesis of these various prostaglandins in intact bladders. No prostaglandins could be detected in the mucosal medium.
Neither iPGE, nor iPGF2, could be detected in the serosal medium in the basal state or after stimulation with AVP or DDAVP. Synthesis of iPGE2 was 2.72 +0.32 pmol/min per hemibladder under basal conditions, and increased to 5.96±0.63 pmol/min per hemibladder in the presence of arachidonic acid (10 ,uM), the specific precursor of PGE2 (P < 0.005) (Table III) .
Incubation with naproxen (100 ,uM) decreased basal iPGE2 synthesis to levels <0.07 pmol/min per hemibladder (Table III) . Acetaminophen (300 ,uM) inhibited basal iPGE2 synthesis by 60% compared with paired control hemibladders (P < 0.05) (Table III) , thus confirming that acetaminophen acts as an inhibitor of prostaglandin synthesis in toad bladder.
We next investigated the effects of AVP and DDAVP on iPGE2 synthesis. AVP (13 (Fig. 2) . This peak corresponds to the standards for PGE2 and TXB2, which comigrate in this solvent system. In solvent system II, which allows separation of PGE2 and TXB2, three separate peaks of '4C-labeled prostaglandins appeared, corresponding to the authentic standards of PGE2, TXB2, and PGA2. It (Table IV) . Incubation with arachidonic acid (10 ,uM) increased both iPGE2 and iTXB2 synthesis by 120%, whereas naproxen (100 ,uM) inhibited iPGE2 synthesis by 34% and iTXB2 synthesis by 38% (Table IV) . Neither AVP (13 nM) nor DDAVP (130 nM) altered epithelial cell iPGE2 or iTXB2 synthesis compared with control values (Table IV) , confirming the results obtained in whole bladders (Table III) . In contrast, Zusman et al. (8) reported that AVP caused a 40-fold increase in the release of total counts and arachidonic acid, with a proportionate increase in the synthesis of PGE2 in bladders prelabeled with [3H]arachidonic acid. To determine whether this discrepancy with our results might be due to differences in the radiolabel used, we repeated our prelabeling experiments using [3H]arachidonic acid and a protocol comparable to the one used by Zusman et flow was significantly increased in the AVP-treated hemibladders compared with control (48.7±9.2 vs. 1.9±+0.3 ,lI/min, P < 0.025). Thin-layer radiochromatography of the serosal medium showed a similar pattern of radiolabeled products, as shown for the 14C-label experiments in Fig. 3 , with peaks corresponding to the TXB2, PGE2, PGA2, arachidonic acid, and neutral lipid standards. Table V gives the results for the radiolabel comigrating with the corresponding standards from control and AVP-treated hemibladders. There were no significant differences in either prostaglandin or arachidonic acid release between control and experimental hemibladders.
DISCUSSION
Our studies demonstrate that the toad urinary bladder, and specifically its vasopressin-sensitive cell, the epithelial cell, produces two prostaglandins, PGE2 and TXB2. This has been confirmed by two independent techniques, radioimmunoassay and thin-layer radiochromatography. Furthermore, there is no evidence that AVP or DDAVP stimulates prostaglandin synthesis as measured by either techni(lue.
Based on these results, we propose an alternate hypothesis to characterize the interrelation of vasopressin, water permeability, and prostaglandins in this tissue. In this scheme, it is the basal rate of endogenous prostaglandin synthesis that modulates the water flow response to vasopressin. In the absence of vasopressin, prostaglandins have no effect on water permeability. Also, vasopressin does not initiate any negative feedback response via increases in prostaglandin synthesis, as has been proposed in the past (8) .
The present studies support this alternate hypothesis. Toad bladders, and specifically the epithelial cells, synthesize PGE2 and thromboxane as determined by radioimmunoassay and thin-layer chromatography. Extrapolation ofthe data from epithelial cell incubation indicates that these cells account for most, if not all, ofthe iPGE2 synthesis in the whole bladder. Inhibition of basal prostaglandin synthesis by the cyclooxygenase inhibitor naproxen markedly enhances the water flow response to vasopressin without affecting basal water flow. As with naproxen, acetaminophen also inhibited prostaglandin synthesis and enhanced hormone-stimulated, but not basal water flow. These studies demonstrate that acetaminophen acts as a prostaglandin synthesis inhibitor in toad bladders, as has been reported in renal medullary slices (26) . When, on the other hand, endogenous prostaglandin synthesis was stimulated by administration of arachidonic acid, basal water flow was unaffected, but hormone-stimulated water flow was markedly inhibited. These data confirm the important role played by prostaglandins in modulating the response to vasopressin. Radioimmunoassay studies revealed that in intact bladders, iPGE2 synthesis was not altered by AVP. Similarly, AVP had no effect on either iPGE2 or iTXB2 synthesis by isolated epithelial cells. These results were confirmed by a second, independent method, thin-layer radiochromatography. Vasopressin These findings are supported by the earlier work of Wong et al. (9) , who found that vasopressin in the toad bladder had no effect on the synthesis of PGE as determined by bioassay. A recent preliminary report has failed to observe any increase in iPGE2 synthesis by vasopressin in the toad bladder (27) . However, these results and ours are at odds with those of Zusman et al. (8) . These workers reported that vasopressin stimulated toad bladder PGE synthesis in a dosedependent manner. At the concentration of AVP used in our study (13 nM), they reported a sixfold increase in iPGE synthesis. After prelabeling toad bladders with [3H]arachidonic acid, they found a 40-fold increase in radiolabeled arachidonic acid release and a proportionate increase in radiolabeled PGE2 synthesis. Based on these results they proposed that vasopressin increased prostaglandin synthesis in the toad bladder by activating phospholipase, and thus increasing the amount of arachidonic acid available for prostaglandin synthesis. This increased prostaglandin production would in turn inhibit vasopressin's effect on water flow, thus closing a negative feedback loop.
There are several possible explanations for the discrepancies between our results and those of other workers (8, 28) . The first involves the differences between the radioimmunoassay systems used. These investigators measured PGE synthesis after conversion of PGE to PGB, followed by radioimmunoassay for PGB. Another report from the same laboratory (29) demonstrated that this technique greatly overestimated PGE concentrations in human urine in comparison with measurements of PGE2 by gas chromatographymass spectroscopy. This discrepancy was attributed to possible cross-reactivity of the antiserum with a PGE metabolite. However, direct measurements of PGE2 and its major urinary metabolite did not consistently account for the discrepancy. This raises the possibility of nonspecific interference with the radioimmunoassay for PGB. Therefore, results for PGE2 synthesis obtained with the PGB radioimmunoassay system must be interpreted with caution.
For a number of reasons, we feel that the radioimmunoassay for PGE2 used in the present study reflects actual PGE2 synthesis. The antiserum employed in our studies was highly specific for PGE2. Serial dilution of samples up to 1:50 revealed no evidence of nonspecific interference with antigenantibody binding. Radioimmunoassay measured virtually all of the exogenous PGE2 added to the serosal bath of bladders in which endogenous prostaglandin production was blocked by naproxen. Furthermore, this was not altered by administration of AVP. In addition, the results with administration of naproxen and arachidonic acid confirm that appropriate changes in iPGE2 synthesis can be detected with this method.
Because we employed a different buffer system than used in the previous reports (8, 28) , we considered the possibility that this might account for the discrepancies between these reports and the present study. However, iPGE2 synthesis was not altered by AVP when we employed a bicarbonate-buffered Ringer's similar to that used by Zusman et al. (8) . In the report of Burch et al. (28) , bladders were allowed to equilibrate for 2 h before measurement of iPGE2 synthesis. As shown in the present report, iPGE2 synthesis decreased to very low levels at this time, comparable to the levels reported by Burch et al. (28) . Even at these low levels, however, iPGE2 synthesis was not increased by AVP in our studies. Thus the factor of time does not appear to account for the differences between our results and those of previous reports (8, 28) . The remainder of our studies were performed in a time frame comparable to that used by Zusman et al. (8) .
We investigated another possible explanation for the difference between the present study and the previous reports. Vasopressin might stimulate synthesis of some prostaglandins other than PGE2 or TXB2, which might be measured as PGE by the PGB assay system, but not cross-react with the specific PGE2 antiserum used in our studies. Radioimmunoassay failed to detect any PGE1 or PGF2a in our study, however, and thin-layer radiochromatography indicated that the only labeled prostaglandins produced by the toad bladder in the presence of [14C]arachidonic acid were PGE2 and TXB2.
Although (8) , who reported a 40-fold increase in arachidonic acid release from prelabeled bladders in response to AVP with a proportionate increase in PGE2 synthesis. As has been suggested by others (30) , such large increases in arachidonate release in the absence of some method of trapping the released arachidonate (e.g., addition of albumin to the medium) are unusual, as free arachidonic acid is rapidly reincorporated into phospholipids. Clearly, our experiments provide no evidence for increased release of arachidonate or increased prostaglandin synthesis. Incomplete washing of bladders might account for the large increases in the appearance of radiolabel in the serosal medium in the study of Zusman et al. (8) . If this were the case, then vasopressin-stimulated water flow across the bladders might passively wash out nonincorporated products into the serosal bath.
The present study also demonstrate that toad bladder epithelial cells produce TXB2. TXB2 is the stable metabolite of the active but quite short-lived parent compound, TXA2. The role, if any, of TXA2 in modulating vasopressin's action is not clear from the present studies. An interaction of thromboxane with vasopressin has been postulated (28, 31) . However, studies with the prostaglandin endoperoxide-thromboxane agonist (15S)-hydroxy-1 1a, 9a-(epoxymethano)prosta-5Z, 13E-dienoic acid have revealed conflicting results. Burch and Halushka (31) demonstrated that this agent stimulated basal and vasopressin-stimulated water flow, whereas Ludens and Taylor (32) found that it inhibited vasopressin-stimulated water flow. Imidazole (1 mM), a thromboxane synthesis inhibitor, inhibited vasopressin-stimulated water flow, but at this concentration this agent also increased iPGE2 synthesis (28) . At higher doses (50 mM), imidazole inhibited both iTXB2 and iPGE synthesis and enhanced vasopressin-stimulated water flow (28) . Therefore, its effect cannot be clearly attributed to inhibition of thromboxane synthesis.
Our finding of TXB2 synthesis by the toad bladder confirms the recent report of Burch et al. (28) ; however, in contrast to these investigators we find no evidence that vasopressin increases thromboxane synthesis. The reasons for the discrepancy are not clear.
Although the results of the present study differ from those of several previous reports, there are data from a variety of systems that tend to support our concept. In vivo studies in Brattleboro rats and in man have demonstrated an increase in urinary PGE2 excretion in response to AVP administration (12, 33) . However, results with the administration of the nonpressor analogue of AVP, DDAVP, are conflicting. Dunn et al. (12) and Walker and Frolich (13) reported an increase in urinary PGE2 excretion in Brattleboro rats given DDAVP. Two reports on human diabetes insipidus, however, failed to find any increase in urinary PGE2 excretion in response to DDAVP (14, 15) .
A possible explanation for the conflicting results may relate to the duration of exposure to hormone. The studies demonstrating increased urinary PGE2 excretion in rats with congenital diabetes insipidus involved chronic administration of DDAVP. It may be that chronic hormonal stimulation of the collecting tubule may lead to increased prostaglandin synthesis, possibly secondary to changes in, for example, medullary composition and the attendant alterations in medullary blood flow.
Furthermore, prostaglandin synthesis in cultured renomedullary interstitial cells was stimulated by AVP but not by DDAVP (10) . Similarly, pressor doses of AVP increased prostaglandin and thromboxane synthesis in isolated perfused rabbit kidney, whereas e(Iual doses of DDAVP did not (11) . These data thus raise the possibility that it is not the antidiuretic activity of vasopressin on the collecting tubule, but rather its pressor activity elsewhere in the kidney that acutely stimulates renal prostaglandin synthesis. Chronic administration of vasopressin, on the other hand, could influence medullary prostaglandin synthesis and excretion indirectly, by changing renal medullary blood flow or medullary solute composition for example. This cooncept is consistent with our finding that neither AVP nor DDAVP stimulates prostaglandin synthesis in the toad urinary bladder, an analogue of the mammalian renal collecting tubule.
Although our results do not support the presence in the toad bladder of a negative feedback loop in which vasopressin stimulates prostaglandin synthesis, they do support the importance of the basal rate of prostaglandin synthesis as a modulator of vasopressin's action. Clearly, factors that influence the basal rate of prostaglandin synthesis will have a marked influence on vasopressin response.
